» Articles » PMID: 14996614

Angiotensin As a Target for the Treatment of Alzheimer's Disease, Anxiety and Depression

Overview
Publisher Informa Healthcare
Specialty Pharmacology
Date 2004 Mar 5
PMID 14996614
Citations 27
Authors
Affiliations
Soon will be listed here.
Abstract

The brain renin-angiotensin system (RAS), which is comprised of a variety of peptides including angiotensin II, angiotensin III and angiotensin IV acting on AT<inf>1</inf>, AT<inf>2</inf> and AT<inf>4</inf> receptors, is important in cognition and anxiety. Perturbation of the RAS improves basal cognition and reverses age-, scopolamine-, ethanol- and diabetes-induced deficits. In studies of dementias and Alzheimer's disease (AD), some studies have shown that antihypertensive drugs, including angiotensin-converting enzyme inhibitors, have some moderate effects on cognitive decline, but that the angiotensin receptor antagonist losartan has a significantly beneficial effect. These findings suggest that angiotensin receptor ligands may have potential in the prevention or even reversal of vascular dementias and AD. With respect to depression and anxiety, there is similar experimental evidence from animal models that drugs acting on the RAS may be antidepressant or anxiolytic, but insufficient clinical data exist. Such effects, if proven, could promote the use of such agents in the treatment of hypertension coexisting with depression or anxiety.

Citing Articles

ADME profiling, molecular docking, DFT, and MEP analysis reveal cissamaline, cissamanine, and cissamdine from L.f. as potential anti-Alzheimer's agents.

Alhawarri M, Al-Thiabat M, Dubey A, Tufail A, Fouad D, Alrimawi B RSC Adv. 2024; 14(14):9878-9891.

PMID: 38528929 PMC: 10961956. DOI: 10.1039/d4ra01070a.


Effects of esaxerenone on blood pressure, urinary albumin excretion, serum levels of NT-proBNP, and quality of life in patients with primary aldosteronism.

Yoshida Y, Fujiwara M, Kinoshita M, Sada K, Miyamoto S, Ozeki Y Hypertens Res. 2023; 47(1):157-167.

PMID: 37717115 DOI: 10.1038/s41440-023-01412-w.


Systematically exploring repurposing effects of antihypertensives.

Shahn Z, Spear P, Lu H, Jiang S, Zhang S, Deshmukh N Pharmacoepidemiol Drug Saf. 2022; 31(9):944-952.

PMID: 35689299 PMC: 9545793. DOI: 10.1002/pds.5491.


Quality of Life of Primary Aldosteronism Patients by Mineralocorticoid Receptor Antagonists.

Yoshida Y, Yoshida R, Shibuta K, Ozeki Y, Okamoto M, Gotoh K J Endocr Soc. 2021; 5(4):bvab020.

PMID: 33817540 PMC: 7993577. DOI: 10.1210/jendso/bvab020.


Hypertension Treatment Modality and Suicide Risk Among Veterans in Veterans Health Administration Care From 2015 to 2017.

Dent K, Griffin C, McCarthy J, Katz I JAMA Netw Open. 2020; 3(10):e2020330.

PMID: 33044550 PMC: 7550968. DOI: 10.1001/jamanetworkopen.2020.20330.